Axplora CEO Martin Meeson Highlights CDMOs’ Role in API Quality and Supply Chain Security

Martin Meeson, CEO of Axplora, discussed the responsibilities of contract development and manufacturing organizations (CDMOs) in maintaining the quality of active pharmaceutical ingredients (APIs) and safeguarding supply chain security. He outlined how CDMOs play a critical role in ensuring that APIs meet stringent regulatory standards while also addressing challenges related to global supply chain reliability.

Meeson emphasized that CDMOs are integral to the pharmaceutical industry’s ability to deliver safe and effective medications. He highlighted their involvement in every stage of API production, from development to large-scale manufacturing. According to Meeson, these organizations must adhere to rigorous quality control measures and comply with international regulations to ensure consistency and safety in API production. Additionally, he noted that CDMOs contribute significantly to mitigating risks associated with supply chain disruptions by implementing robust strategies for sourcing raw materials and managing logistics.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 30, 2025

Related posts:

Study Reveals Impact of Optimism and Pessimism on Resilience and Health Behaviors During COVID-19 QIAGEN PGXI System Offers Quicker, More Precise Pharmacogenomic Insights Only 1% of Patients Are Truly Allergic to Penicillin, Testing Can Improve Access to First-Line Treatments ASPA and CRISIL to Release 2025 Counterfeiting Report Analyzing Risks Across Key Indian Sectors

Author

Mark Chiang